Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Language Podcast: 重磅交易, 亚太药企如何度过资本寒冬, 减肥药风口

New and Hot Trends to Watch

Executive Summary

The latest China biopharma trends, including recent multimillion dollar deals by biotech firms, companies preparing for the worst as the 'capital winter' lingers, and GLP-1 agents for obesity are discussed by Brian Yang in Beijing and Dexter Yan in Shanghai in this latest Chinese-language podcast.



在本期的节目中,中国主编杨宏新Brian和资深记者严洁Dexter首先讨论了最近的几个国内生物制药企业的重磅交易,这些交易包括Bliss Biopharma和卫材(Eisai)签署的围绕HER2靶点的抗体偶连体(ADC)的交易。

这些交易有哪些特点呢?在行业整体恢复乏力的情况下,这些交易的达成对于整个中国生物制药行业今后的发展方向透露了哪些信息 (Also see "Can BlissBio’s HER2-Targeting ADC Challenge Enhertu In Breast Cancer?" - Scrip, 10 May, 2023.)?

接下来的话题是刚刚在新加坡举办的亚洲生物制药合作论坛 (Asia Bio Partnering Forum)。这是第一个线下举办的亚太地区的生物制药合作会议。Brian在此会议上主持了一个上市商业化的专题讨论。他分享了和来自国内,新加坡,韩国药企的分享和自己的体会,尤其是最近在资本严冬继续的情况下,亚太药企在创新和灵活性上下功夫,在融资方面有哪些新动向呢? (Also see "'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better" - Scrip, 8 May, 2023.)



减肥药是否会成为继抗肿瘤药之后成为中国药企蜂拥的又一个风口呢? (Also see "Mazdutide Consolidates Potential Efficacy Lead In China GLP-1 Obesity Race" - Scrip, 16 May, 2023.)





Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts